Abstract Number: 1456 • ACR Convergence 2022
Latin-American Systemic Lupus Erythematosus Clusters
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management…Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…Abstract Number: 1631 • ACR Convergence 2022
Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…Abstract Number: 1711 • ACR Convergence 2022
The Cellular Basis for Type I Interferon Production Following Ultraviolet Light Stimulated Cyclic-GMP-AMP Synthase Activation in the Skin
Background/Purpose: SLE patients characteristically have a type I interferon (IFN-I) signature in peripheral blood cells and this same signature is prominent in lesional and non-lesional…Abstract Number: 1932 • ACR Convergence 2022
Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response…Abstract Number: 2063 • ACR Convergence 2022
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to…Abstract Number: 2081 • ACR Convergence 2022
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…Abstract Number: 2101 • ACR Convergence 2022
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…Abstract Number: 2225 • ACR Convergence 2022
Physical Inactivity Is Associated with Increased Expression of T Cell Inflammatory Genes in Systemic Lupus
Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…Abstract Number: 0062 • ACR Convergence 2022
Comparing Alzheimer’s Disease Risk in Patients with Chronic Inflammatory Autoimmune Diseases: A Medicare Cohort Study
Background/Purpose: Chronic inflammatory diseases have been associated with an increased risk of Alzheimer’s disease (AD), yet emerging research in rheumatoid arthritis (RA) and psoriasis suggests…Abstract Number: 0115 • ACR Convergence 2022
Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff
Background/Purpose: SLE disproportionately affects patients of color. Medication nonadherence is more common among patients of color with SLE and is associated with worse health outcomes.…Abstract Number: 0328 • ACR Convergence 2022
Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis
Background/Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some…Abstract Number: 0346 • ACR Convergence 2022
Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
Background/Purpose: Hydroxychloroquine (HCQ) is a medication used in most patients with systematic lupus erythematous (SLE). It is generally a safe; however, it can cause retinal…Abstract Number: 0368 • ACR Convergence 2022
Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
Background/Purpose: Severe thrombocytopenia in systemic lupus erythematosus (SLE) is characterized by poor response to glucocorticoids and frequent relapses. Information regarding the risk of relapse with…Abstract Number: 0633 • ACR Convergence 2022
Identification of Systemic Lupus Erythematosus Endotypes by Analysis of Inflammatory and Immunologic Gene Expression Signatures
Background/Purpose: One of the hallmarks of SLE is clinical and molecular heterogeneity. Recent work has leveraged next-generation sequencing techniques to identify molecular signatures characteristic of…
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 150
- Next Page »